Changes in chromatin accessibility landscape and histone H3 core acetylation during valproic acid-induced differentiation of embryonic stem cells.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study in mouse embryonic stem cells without clinical human data.
PubMed 34955095 · doi:10.1186/s13072-021-00432-5
What was done
The authors investigated the epigenetic mechanisms through which the histone deacetylase inhibitor valproic acid (VPA) promotes directed differentiation of mouse embryonic stem cells (mESCs). They treated mESCs with VPA and profiled chromatin accessibility, transcription factor footprinting, and histone modifications using ATAC-seq and CUT&RUN assays.
What was found
The abstract reports qualitative mechanistic shifts without specific numerical values. VPA treatment induced a global increase in histone H3 core acetylation (specifically H3K56ac), enriched at loci linked to cytoskeletal organization and morphogenesis. VPA altered linker histone H1 subtype distribution and the total H1-to-nucleosome ratio. Chromatin accessibility shifted at genes regulating CDK serine/threonine kinase activity and DNA unwinding, as well as specific differentiation loci including Lefty, Tnnt2, and Hopx. Transcription factor footprinting showed increased binding of mesoderm- and endoderm-associated factors alongside reduced occupancy of pluripotency factors POU5F1 (OCT4) and SOX2.
Why it matters
This study provides genome-wide chromatin and histone mapping of VPA-induced early lineage commitment in stem cells, clarifying how histone deacetylase inhibition facilitates exit from pluripotency toward specific developmental fates.
Limits
The study is restricted to in vitro murine embryonic stem cells and did not evaluate human cells. The abstract reports no exact quantitative effect sizes, replicate numbers, or functional in vivo differentiation outcomes.
Cited by
- supports Valproate acts as a histone deacetylase inhibitor that globally affects histones across the genome.